12:13 PM EDT, 10/05/2026 (MT Newswires) -- Berenberg reiterated its buy rating for Glanbia (GL9.IR, GLB.L), saying it sees a "clear path" toward continued market share expansion for the nutrition and wellness company. "Our analysis of LLM-based discovery shows that Glanbia is a leader in AI visibility and brand perception, with its outlook compounded by ongoing structural tailwinds across all three of its businesses. This leads to attractive c5.8% annual organic growth to 2028, 250bp faster than its food and ingredients peer average," according to a Monday note. Analysts expect the company to deliver an EPS growth of 14% through 2028, driven by strong top-line growth and an estimated 40 basis-point annual adjusted EBITDA margin expansion. The stock's price target was increased to 24.30 euros from 22.60 euros. In addition, the research firm updated its Glanbia model for the first-half results and latest company commentary, and revised its margin assumptions through 2030. Berenberg also raised its 2026 adjusted EPS forecast by 6.8%, after "meaningful" upgrades to full-year guidance in the first half.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.